Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Chlamydia trachomatis-induced salpingitis in mice.

C E Swenson, E Donegan, J Schachter

The Journal of Infectious Diseases

|December 1, 1983

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Same author

Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285].

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Same author

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Researchers developed a mouse model for salpingitis using Chlamydia trachomatis. This model helps understand the pathogenesis of genital infections caused by this bacterium.

Area of Science:

Microbiology
Immunology
Pathogenesis

Background:

Chlamydia trachomatis infections can lead to serious reproductive health issues, including salpingitis.
Understanding the pathogenesis of C. trachomatis genital infections is crucial for developing effective treatments and prevention strategies.

Purpose of the Study:

To establish and characterize a mouse model of salpingitis induced by the mouse pneumonitis biovar of Chlamydia trachomatis.
To investigate the inflammatory response, pathogen dissemination, and antibody production during C. trachomatis genital infection in mice.

Main Methods:

Inoculation of the mouse pneumonitis biovar of C. trachomatis into the ovarian bursa of mice.
Monitoring of inflammatory responses, pathological changes (salpingitis, oviductal occlusion, hydrosalpinx), and pathogen recovery.

Related Experiment Videos

Detection of IgG antibodies against the C. trachomatis agent.

Main Results:

Inoculation led to acute and chronic inflammation, peaking at 6-9 days post-inoculation, with oviductal lumen occlusion observed by day 14.
C. trachomatis was recoverable from genital tissues up to 21 days post-inoculation.
IgG antibodies were detected by day 7, peaking by days 21-30, and hydrosalpinx was observed by days 25-30.

Conclusions:

The developed mouse model effectively replicates key features of C. trachomatis-induced salpingitis.
This model provides a valuable tool for studying the pathogenesis of C. trachomatis genital infections and evaluating potential therapeutic interventions.